|1.||Stroes, Erik S G: 6 articles (11/2014 - 05/2010)|
|2.||Kastelein, John J P: 5 articles (03/2014 - 05/2010)|
|3.||Visser, Maartje E: 4 articles (05/2012 - 05/2010)|
|4.||Raal, Frederick J: 3 articles (11/2015 - 03/2015)|
|5.||Donovan, Joanne M: 3 articles (03/2015 - 05/2012)|
|6.||Santos, Raul D: 3 articles (03/2015 - 11/2014)|
|7.||Baker, Brenda F: 3 articles (02/2015 - 05/2010)|
|8.||Watts, Gerald F: 3 articles (03/2014 - 01/2012)|
|9.||Tribble, Diane L: 3 articles (11/2012 - 05/2010)|
|10.||Burnett, John R: 3 articles (01/2012 - 10/2006)|
03/01/2012 - "Mipomersen: a safe and effective antisense therapy adjunct to statins in patients with hypercholesterolemia."
01/01/2012 - "Safety and efficacy of mipomersen in patients with severe hypercholesterolemia was evaluated. "
10/01/2014 - "Mipomersen is a promising therapy in the management of hypercholesterolemia: a meta-analysis of randomized controlled trials."
01/01/2012 - "Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy."
03/01/2015 - "In the mipomersen group in patients with Lp(a) levels >30 or >50 mg/dL, attainment of Lp(a) values ≤30 or ≤50 mg/dL was most frequent in homozygous FH and severe hypercholesterolemia patients. "
|2.||Hyperlipoproteinemia Type II (Familial Hypercholesterolemia)
12/01/2011 - "The efficacy of mipomersen in treating patients with severe heterozygous or homozygous familial hypercholesterolemia with cardiovascular complications has been recently assessed. "
03/01/2012 - "Clinical trials have demonstrated that mipomersen reduces LDL-C up to 44% in patients with familial hypercholesterolemia and patients with significantly elevated LDL despite taking maximum doses of statins. "
08/01/2010 - "In phase 3 clinical trials, mipomersen has been shown to significantly reduce LDL-c in patients with homozygous and heterozygous familial hypercholesterolemia on maximally tolerated lipid-lowering therapy. "
10/01/2007 - "Studies are ongoing to further define the safety, efficacy, and pharmacokinetics of ISIS 301012 as add-on therapy in patients with heterozygous and homozygous familial hypercholesterolemia. "
08/01/2014 - "Mipomersen is a second-generation antisense oligonucleotide indicated as an adjunct therapy for homozygous familial hypercholesterolemia (HoFH). "
|3.||Cardiovascular Diseases (Cardiovascular Disease)
08/01/2013 - "A pooled analysis of cardiovascular events in phase III trials with mipomersen did not provide evidence for either a positive or negative effect on cardiovascular disease. "
08/01/2010 - "Mipomersen is a new agent to lower LDL-c in patients at increased risk of cardiovascular disease and/or intolerant to statins. "
05/01/2012 - "A randomized, double-blind, placebo-controlled study was conducted to investigate the safety and efficacy of mipomersen, an apolipoprotein B-100 (apoB) synthesis inhibitor, in patients who are statin intolerant and at high risk for cardiovascular disease (CVD). "
02/01/2011 - "mipomersen shows promise as an adjunctive agent by reducing apoB-containing lipoproteins in patients at high risk of atherosclerotic cardiovascular disease who are not at target or are intolerant of statins. "
03/01/2012 - "Mipomersen is an antisense oligonucleotide inhibitor of apolipoprotein (apo) B-100 currently in phase 3 of development for the treatment of hyperlipidemia in patients with a high risk for cardiovascular disease. "
03/01/2015 - "We aimed to perform a meta-analysis of all published randomized controlled trials comparing safety and efficacy of mipomersen with placebo in adults with dyslipidemia. "
03/01/2015 - "Efficacy and safety of mipomersen in treatment of dyslipidemia: a meta-analysis of randomized controlled trials."
12/01/2012 - "Dyslipidemia: Phase III trial of mipomersen in heterozygous FH."
11/01/2011 - "In the treatment of hypercholesterolemia, the antisense therapy mipomersen may provide a possible treatment option for patients with treatment-resistant dyslipidemia."
01/01/2013 - "More recently, promising novel compounds aimed at other molecular targets are being studied for the treatment of severe dyslipidemia: Lomitapide, Mipomersen, PCSK9 inhibitors and HDL-enhancers. "
|5.||Coronary Artery Disease (Coronary Atherosclerosis)
04/01/2013 - "Multinational phase III trials of mipomersen as adjunctive therapy were completed in patients with HoFH, severe FH, heterozygous FH (HeFH) with coronary artery disease (CAD), and in those with hypercholesterolaemia at high risk of CAD. "
11/06/2012 - "This double-blind, placebo-controlled, phase 3 trial randomized patients with HeFH and coronary artery disease on maximally tolerated statin and LDL-C ≥2.6 mmol/L (≥100 mg/dL) to weekly subcutaneous mipomersen 200 mg or placebo (2:1) for 26 weeks. "
04/01/2013 - "Data from a study in 123 patients with heterozygous FH and coronary artery disease on maximally tolerated lipid-lowering therapy were used to evaluate in what percentage adding mipomersen resulted in lipid-levels below apheresis-thresholds. "
11/06/2012 - "We evaluated mipomersen, an apolipoprotein B synthesis inhibitor, to further lower LDL-C in HeFH patients with coronary artery disease. "
11/06/2012 - "Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease."
|1.||Apolipoproteins B (ApoB)
|3.||Apolipoprotein B-100 (Apo B 100)
|10.||microsomal triglyceride transfer protein
|1.||Blood Component Removal (Apheresis)